Key Takeaways
- Clinical Bottom Line
- Managing the Hemodynamic Collapse of Cirrhosis
Clinical Bottom Line
| Pharmacologic Agent | Mechanism of Action | Primary Indication in Cirrhosis |
|---|---|---|
| Octreotide / Terlipressin | Direct somatostatin analog inducing marked splanchnic arterial vasoconstriction. | First-line continuous infusion for acute variceal hemorrhage. |
| Intravenous Albumin (25%) | Massive plasma volume expansion; profound anti-inflammatory/antioxidant properties. | Post-large volume paracentesis (LVP); SBP management; HRS treatment. |
| Non-Selective Beta Blockers | Reduces cardiac output and splanchnic blood flow (via beta-2 blockade). | Primary and secondary prophylaxis for esophageal varices. |
Managing the Hemodynamic Collapse of Cirrhosis
Advanced portal hypertension triggers profound, pathological splanchnic vasodilation mediated by overwhelming local nitric oxide release. This draws massive volumes of blood into the gut, starving the systemic circulation and tricking the kidneys into severe sodium/water retention (ascites) and eventual ischemic failure (Hepatorenal Syndrome – HRS).
The Role of Albumin and Vasoconstrictors
Albumin is not utilized in hepatology merely to correct a low serum protein laboratory value; it is deployed as a powerful, multi-modal drug. In the setting of Spontaneous Bacterial Peritonitis (SBP), administering 1.5 g/kg of albumin on Day 1 dramatically reduces the incidence of HRS type 1 and slashes mortality by sequestering inflammatory cytokines. Simultaneously, administering potent splanchnic vasoconstrictors (like Terlipressin or continuous Octreotide drips) directly reverses the catastrophic splanchnic vasodilation, driving central blood volume back up and mechanically reducing portal portal pressures prior to variceal banding.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
